The consumer genetics firm will soon be able to team with other drug companies as it mines its genotypic database for new disease pathways.
23andMe Raises FY2023 Guidance as Q3 Revenues Increase 18 Percent
Following a strong holiday season for consumer genetic tests and growth in its telehealth business, 23andMe expects a smaller full-year net loss than previously estimated.
23andMe Fiscal Q2 Revenues Grow 37 Percent as Firm Leans Into DTC Primary Care Strategy
Telehealth services from the 2021 acquisition of Lemonaid Health fueled much of the growth for 23andMe in the quarter ended Sept. 30.
23andMe Gains FDA Clearance for Simvastatin Pharmacogenetic Report
The new clearance removes the need for confirmatory testing to use 23andMe's SLCO1B1 report before prescribing simvastatin for hyperlipidemia.
Dyslexia GWAS Leads to Dozens of Risk Loci, Polygenic Risk Score
A genome-wide association study that included more than a million cases or controls led to 42 genetic risk loci for dyslexia, along with a polygenic risk score.